Liraglutide

CAS : 204656-20-2

Ref. 3D-PGL-3781-PI

Informations sur le produit

• Nom: Liraglutide
• Synonymes: Liraglutida [INN-Spanish], Liraglutidum [INN-Latin], Nn 2211, Nn2211, Unii-839I73S42A
• CAS: 204656-20-2

Description

Liraglutide is a glucagon-like peptide-1 analog that has been shown to be an effective treatment for obesity. Liraglutide targets the adipose tissue and reduces the amount of glucose in the blood by increasing insulin sensitivity, lowering food intake, and reducing appetite. In addition, Liraglutide has been shown to suppress postprandial hyperglycemia and lower plasma glucose levels in patients with type 2 diabetes mellitus. Liraglutide also inhibits neuronal death induced by apoptotic stimuli, which may have potential use as a model system for neurodegenerative diseases such as Parkinson's disease. Liraglutide has also been shown to be an effective therapy for infectious diseases including Crohn's disease and ulcerative colitis. This drug has shown some effectiveness against atherosclerosis in animal models by inducing apoptosis in macrophages that are associated with lesions. It has also been found to have beneficial

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 3,751.29 g/mol
• Formule: C₁₇H₂₆₅N₄₃O₅₁
• Degré de pureté: Min. 95%